Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- General & Internal (3)
- 5-Fluorouracil;; cancer;; chemotherapy;; colorectal;; cure;; metastatic (1)
- ACUTE MYELOID-LEUKEMIA;; SOUTHWEST-ONCOLOGY-GROUP;; COMPLETE REMISSION;; AGE;; CYTARABINEDAUNORUBICIN;; DAUNORUBICIN;; CYTOGENETICS;; INDUCTION;; CHEMOTHERAPY;; FORMULATION;; Hematology (1)
- Acute myeloid leukemia;; recombinant interleukin-2;; phase 3;; immunotherapy;; adjuvant therapy;; ACUTE MYELOGENOUS LEUKEMIA;; NATURAL-KILLER-CELLS;; HIGH-DOSE CYTARABINE;; GROUP-B;; INTENSIFICATION THERAPY;; IN-VIVO;; CANCER;; ADULTS;; SURVIVAL;; TRANSPLANTATION;; Oncology (1)
- Acute/genetics/ metabolism/ mortality;; Male;; Middle Aged;; Mutation;; Neoplasm Proteins/genetics/metabolism;; RNA (1)
-
- Anticoagulation;; atrial fibrillation;; stroke;; MOLECULAR-WEIGHT HEPARIN;; ANTICOAGULATION THERAPY;; METAANALYSIS;; DABIGATRAN;; MANAGEMENT;; STROKE;; TRIAL;; Cardiac & Cardiovascular Systems;; Peripheral Vascular Disease (1)
- B-CELLS;; GENOMIC ABERRATIONS;; SURVIVAL;; INHIBITOR;; RECEPTOR;; EXPRESSION;; CAL-101;; ACTIVATION;; MUTATION;; DISEASE;; Medicine (1)
- Busulfan;; Bone marrow transplant;; Elderly;; Pharmacokinetics;; BONE-MARROW-TRANSPLANTATION;; HIGH-DOSE BUSULFAN;; DAILY IV BUSULFAN;; INTRAVENOUS BUSULFAN;; BODY-WEIGHT;; VENOOCCLUSIVE DISEASE;; CONDITIONING;; THERAPY;; SYSTEMIC EXPOSURE;; OLDER PATIENTS;; CHILDREN;; Oncology;; Pharmacology & Pharmacy (1)
- CHRONIC LYMPHOCYTIC-LEUKEMIA;; CHRONIC MYELOID-LEUKEMIA;; ACQUIRED-RESISTANCE;; CLINICAL RESISTANCE;; THERAPEUTIC TARGET;; ANTIGEN;; RECEPTOR;; POINT MUTATIONS;; GENE MUTATION;; CANCER;; PCI-32765;; Medicine (1)
- CHRONIC LYMPHOCYTIC-LEUKEMIA;; NON-HODGKINS-LYMPHOMAS;; PHASE-II;; FLUDARABINE;; GUIDELINES;; PCI-32765;; RITUXIMAB;; DIAGNOSIS;; LENALIDOMIDE;; THERAPY;; Medicine (1)
- Case-Control Studies;; Disease-Free Survival;; Female;; Gene Expression Regulation (1)
- DEPENDENT CELLULAR CYTOTOXICITY;; NATURAL-KILLER-CELL;; MUTATION STATUS;; PHASE-II;; THERAPY;; ANTIBODY;; DISEASE;; CANCER;; GENE;; CYCLOPHOSPHAMIDE;; Oncology (1)
- DNA METHYLATION;; MUTATION STATUS;; CD38 EXPRESSION;; SURVIVAL;; ABERRATIONS;; EVOLUTION;; AGREEMENT;; IBRUTINIB;; DISEASE;; Hematology (1)
- GAS6;; acute myeloid leukemia;; prognosis;; ACUTE MYELOID-LEUKEMIA;; INTERNAL TANDEM DUPLICATIONS;; RECEPTOR TYROSINE;; KINASES;; AGE 60 YEARS;; GROUP-B;; OLDER PATIENTS;; GROWTH ARREST;; DISTINCT;; GENE;; PROGNOSTIC-SIGNIFICANCE;; PREDICTS ADVERSE;; Oncology;; Hematology (1)
- HIGH-FREQUENCY;; PREFERENTIAL USE;; INFLUENZA-VIRUS;; GENE;; NEUTRALIZATION;; RECEPTORS;; IDIOTYPES;; SUBSETS;; BINDING;; IGM;; Multidisciplinary Sciences (1)
- Leukemic;; Humans;; Leukemia (1)
- Long Noncoding/ biosynthesis/genetics;; RNA (1)
- MICRORNA-EXPRESSION SIGNATURES;; DNA METHYLATION;; OLDER PATIENTS;; PROGNOSTIC IMPACT;; DNMT3A MUTATIONS;; CANCER;; AML;; ISLANDS;; RISK;; HYPERMETHYLATION;; Oncology (1)
- MYELODYSPLASTIC SYNDROMES;; CYTOGENETICS;; FLT3;; Oncology;; Hematology (1)
- Metastatic breast cancer;; long survival;; trastuzumab;; CHEMOTHERAPY;; DYSFUNCTION;; PROGRESSION;; REMISSION;; SURVIVAL;; PATIENT;; TRIALS;; Biotechnology & Applied Microbiology;; Oncology (1)
- Myeloid (1)
- Neoplasm/ biosynthesis/genetics;; Sequence Analysis (1)
- RNA;; Survival Rate;; acute myeloid leukemia;; lncRNAs;; outcome (1)
Articles 1 - 18 of 18
Full-Text Articles in Medicine and Health Sciences
More Than 9 Years Of Continuous Trastuzumab Treatment In Metastatic Breast Cancer Without Cardiac Toxicity: A Case Report And Literature Review, F. Badulescu, A. Badulescu, D. Paul, C. F. Popescu, C. Florescu
More Than 9 Years Of Continuous Trastuzumab Treatment In Metastatic Breast Cancer Without Cardiac Toxicity: A Case Report And Literature Review, F. Badulescu, A. Badulescu, D. Paul, C. F. Popescu, C. Florescu
Journal Articles
The main concern of long-term use of trastuzumab remains its association with potential cardiac side effects. Although these side effects are real, they are probably overemphasized. We report the case of a woman with metastatic breast cancer, who is currently in complete remission, and who received trastuzumab continuously for more than 9 years, without any significant cardiac toxicity.
Outcomes Of Temporary Interruption Of Rivaroxaban Compared With Warfarin In Patients With Nonvalvular Atrial Fibrillation, M. W. Sherwood, J. D. Douketis, M. R. Patel, J. P. Piccini, A. S. Hellkamp, Y. Lokhnygina, A. C. Spyropoulos, G. J. Hankey, D. E. Singer, R. C. Becker, +4 Additional Authors
Outcomes Of Temporary Interruption Of Rivaroxaban Compared With Warfarin In Patients With Nonvalvular Atrial Fibrillation, M. W. Sherwood, J. D. Douketis, M. R. Patel, J. P. Piccini, A. S. Hellkamp, Y. Lokhnygina, A. C. Spyropoulos, G. J. Hankey, D. E. Singer, R. C. Becker, +4 Additional Authors
Journal Articles
Background During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, and the relationship between anticoagulant and outcomes among patients with TI. Methods and Results In the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), a randomized, double-blind, double-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillation, baseline characteristics, management, and outcomes, including …
Phase 2 Trial Of Cpx-351, A Fixed 5:1 Molar Ratio Of Cytarabine/Daunorubicin, Vs Cytarabine/Daunorubicin In Older Adults With Untreated Aml, J. E. Lancet, J. E. Cortes, D. E. Hogge, M. S. Tallman, T. J. Kovacsovics, L. E. Damon, R. Komrokji, S. R. Solomon, J. E. Kolitz, E. J. Feldman, +3 Additional Authors
Phase 2 Trial Of Cpx-351, A Fixed 5:1 Molar Ratio Of Cytarabine/Daunorubicin, Vs Cytarabine/Daunorubicin In Older Adults With Untreated Aml, J. E. Lancet, J. E. Cortes, D. E. Hogge, M. S. Tallman, T. J. Kovacsovics, L. E. Damon, R. Komrokji, S. R. Solomon, J. E. Kolitz, E. J. Feldman, +3 Additional Authors
Journal Articles
CPX-351 is a liposomal formulation of cytarabine: daunorubicin designed to deliver synergistic drug ratios to leukemia cells. In this phase 2 study, newly diagnosed older acute myeloid leukemia (AML) patients were randomized 2: 1 to first-line CPX-351 or 713 treatment. The goal was to determine efficacy and identify patient subgroups that may benefit from CPX-351 treatment. Response rate (complete remission 1 incomplete remission) was the primary end point, with event-free survival (EFS) and overall survival (OS) as secondary end points. The 126 patients entered were balanced for disease and patient-specific risk factors. Overall, CPX-351 produced higher response rates (66.7% vs …
Prognostic And Biologic Significance Of Dnmt3b Expression In Older Patients With Cytogenetically Normal Primary Acute Myeloid Leukemia, C. Niederwieser, J. Kohlschmidt, S. Volinia, S. P. Whitman, K. H. Metzeler, A. K. Eisfeld, K. Maharry, P. Yan, J. E. Kolitz, C. D. Bloomfield, +17 Additional Authors
Prognostic And Biologic Significance Of Dnmt3b Expression In Older Patients With Cytogenetically Normal Primary Acute Myeloid Leukemia, C. Niederwieser, J. Kohlschmidt, S. Volinia, S. P. Whitman, K. H. Metzeler, A. K. Eisfeld, K. Maharry, P. Yan, J. E. Kolitz, C. D. Bloomfield, +17 Additional Authors
Journal Articles
DNMT3B encodes a DNA methyltransferase implicated in aberrant epigenetic changes contributing to leukemogenesis. We tested whether DNMT3B expression, measured by NanoString nCounter assay, associates with outcome, gene and microRNA expression and DNA methylation profiles in 210 older (60 years) adults with primary, cytogenetically normal acute myeloid leukemia (CN-AML). Patients were dichotomized into high versus low expressers using median cut. Outcomes were assessed in the context of known CN-AML prognosticators. Gene and microRNA expression, and DNA methylation profiles were analyzed using microarrays and MethylCap-sequencing, respectively. High DNMT3B expressers had fewer complete remissions (CR; P=0.002) and shorter disease-free (DFS; P=0.02) and overall …
Prolonged Survival In Metastatic Colorectal Cancer Following Chemotherapy, D. Paul, M. Gold, N. Nouraddin
Prolonged Survival In Metastatic Colorectal Cancer Following Chemotherapy, D. Paul, M. Gold, N. Nouraddin
Journal Articles
KEY CLINICAL MESSAGE: The cost of treating metastatic colorectal cancer has increased significantly after the introduction of targeted antivascular therapies. We report the unusual case of a patient with colorectal cancer with several large liver metastases at diagnosis, who was cured after removal of the primary tumor and treatment with 5-FU/LV only.
Prognostic Gene Mutations And Distinct Gene- And Microrna-Expression Signatures In Acute Myeloid Leukemia With A Sole Trisomy 8, H. Becker, K. Maharry, K. Mrozek, S. Volinia, A. K. Eisfeld, M. D. Radmacher, J. Kohlschmidt, K. H. Metzeler, J. E. Kolitz, C. D. Bloomfield, +14 Additional Authors
Prognostic Gene Mutations And Distinct Gene- And Microrna-Expression Signatures In Acute Myeloid Leukemia With A Sole Trisomy 8, H. Becker, K. Maharry, K. Mrozek, S. Volinia, A. K. Eisfeld, M. D. Radmacher, J. Kohlschmidt, K. H. Metzeler, J. E. Kolitz, C. D. Bloomfield, +14 Additional Authors
Journal Articles
No abstract provided.
Recombinant Interleukin-2 In Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia In First Complete Remission, J. E. Kolitz, S. L. George, D. M. Benson, K. Maharry, G. Marcucci, R. Vij, B. L. Powell, S. L. Allen, D. J. Deangelo, Oncology Alliance Clinical Trials, +8 Additional Authors
Recombinant Interleukin-2 In Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia In First Complete Remission, J. E. Kolitz, S. L. George, D. M. Benson, K. Maharry, G. Marcucci, R. Vij, B. L. Powell, S. L. Allen, D. J. Deangelo, Oncology Alliance Clinical Trials, +8 Additional Authors
Journal Articles
BACKGROUNDRecombinant interleukin-2 (rIL-2) induces cellular cytotoxicity against leukemia blasts. Patients with acute myeloid leukemia (AML) in first complete remission (CR) may harbor minimal residual disease that is susceptible to rIL-2-activated effector cells. METHODSIn the Cancer and Leukemia Group B (CALGB) 19808 study, patients with AML in first CR were randomly assigned after all planned chemotherapy to receive a 90-day course of subcutaneously administered rIL-2 or no further therapy. The primary objective was to compare disease-free survival (DFS) between the 2 treatment arms. A total of 534 patients achieved a CR, 214 of whom were randomized. Six courses of low-dose daily …
Resistance Mechanisms For The Bruton's Tyrosine Kinase Inhibitor Ibrutinib, J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. H. Li, J. C. Barrientos, J. C. Byrd, +15 Additional Authors
Resistance Mechanisms For The Bruton's Tyrosine Kinase Inhibitor Ibrutinib, J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. H. Li, J. C. Barrientos, J. C. Byrd, +15 Additional Authors
Journal Articles
BACKGROUND Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important. We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance. METHODS We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy. We then performed functional analysis of identified mutations. …
Validation Of Zap-70 Methylation And Its Relative Significance In Predicting Outcome In Chronic Lymphocytic Leukemia, R. Claus, D. M. Lucas, A. S. Ruppert, K. E. Williams, D. Weng, K. Patterson, M. Zucknick, J. C. Barrientos, K. R. Rai, J. C. Byrd, +13 Additional Authors
Validation Of Zap-70 Methylation And Its Relative Significance In Predicting Outcome In Chronic Lymphocytic Leukemia, R. Claus, D. M. Lucas, A. S. Ruppert, K. E. Williams, D. Weng, K. Patterson, M. Zucknick, J. C. Barrientos, K. R. Rai, J. C. Byrd, +13 Additional Authors
Journal Articles
ZAP-70 methylation 223 nucleotides downstream of transcription start (CpG+223) predicts outcome in chronic lymphocytic leukemia (CLL), but its impact relative to CD38 and ZAP-70 expression or immunoglobulin heavy chain variable region (IGHV) status is uncertain. Additionally, standardizing ZAP-70 expression analysis has been unsuccessful. CpG+223 methylation was quantitatively determined in 295 untreated CLL cases using MassARRAY. Impact on clinical outcome vs CD38 and ZAP-70 expression and IGHV status was evaluated. Cases with low methylation (0.90). Thus, ZAP-70 CpG+223 methylation represents a superior biomarker for TT and OS that can be feasibly measured, supporting its use in risk-stratifying CLL.
Effect Of Age On The Pharmacokinetics Of Busulfan In Patients Undergoing Hematopoietic Cell Transplantation; An Alliance Study (Calgb 10503, 19808, And 100103), J. H. Beumer, K. Owzar, L. D. Lewis, C. Jiang, J. L. Holleran, S. M. Christner, W. Blum, S. Devine, J. E. Kolitz, M. J. Egorin, +5 Additional Authors
Effect Of Age On The Pharmacokinetics Of Busulfan In Patients Undergoing Hematopoietic Cell Transplantation; An Alliance Study (Calgb 10503, 19808, And 100103), J. H. Beumer, K. Owzar, L. D. Lewis, C. Jiang, J. L. Holleran, S. M. Christner, W. Blum, S. Devine, J. E. Kolitz, M. J. Egorin, +5 Additional Authors
Journal Articles
Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and mortality. We hypothesized that busulfan clearance (BuCL) in older patients (> 60 years) would be reduced compared to that in younger patients, potentially explaining observed differences in busulfan tolerability. AML patients in three CALGB hematopoietic cell transplantation studies were treated with a conditioning regimen using IV busulfan, dosed at 0.8 mg/kg. Plasma busulfan concentrations were determined by LC-MS and analyzed by non-compartmental methods. BuCL was normalized to actual (ABW), ideal (IBW), or corrected (CBW) body weight …
Expression And Prognostic Impact Of Lncrnas In Acute Myeloid Leukemia, R. Garzon, S. Volinia, D. Papaioannou, D. Nicolet, J. Kohlschmidt, P. S. Yan, K. Mrozek, D. Bucci, J. E. Kolitz, C. D. Bloomfield, +15 Additional Authors
Expression And Prognostic Impact Of Lncrnas In Acute Myeloid Leukemia, R. Garzon, S. Volinia, D. Papaioannou, D. Nicolet, J. Kohlschmidt, P. S. Yan, K. Mrozek, D. Bucci, J. E. Kolitz, C. D. Bloomfield, +15 Additional Authors
Journal Articles
Long noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides, located within the intergenic stretches or overlapping antisense transcripts of protein coding genes. LncRNAs are involved in numerous biological roles including imprinting, epigenetic regulation, apoptosis, and cell cycle. To determine whether lncRNAs are associated with clinical features and recurrent mutations in older patients (aged >/=60 y) with cytogenetically normal (CN) acute myeloid leukemia (AML), we evaluated lncRNA expression in 148 untreated older CN-AML cases using a custom microarray platform. An independent set of 71 untreated older patients with CN-AML was used to validate the outcome scores using RNA sequencing. Distinctive …
Epigenetics Meets Genetics In Acute Myeloid Leukemia: Clinical Impact Of A Novel Seven-Gene Score, G. Marcucci, P. Yan, K. Maharry, D. Frankhouser, D. Nicolet, K. H. Metzeler, J. Kohlschmidt, K. Mrozek, J. E. Kolitz, C. D. Bloomfield, +21 Additional Authors
Epigenetics Meets Genetics In Acute Myeloid Leukemia: Clinical Impact Of A Novel Seven-Gene Score, G. Marcucci, P. Yan, K. Maharry, D. Frankhouser, D. Nicolet, K. H. Metzeler, J. Kohlschmidt, K. Mrozek, J. E. Kolitz, C. D. Bloomfield, +21 Additional Authors
Journal Articles
Purpose Molecular risk stratification of acute myeloid leukemia (AML) is largely based on genetic markers. However, epigenetic changes, including DNA methylation, deregulate gene expression and may also have prognostic impact. We evaluated the clinical relevance of integrating DNA methylation and genetic information in AML. Methods Next-generation sequencing analysis of methylated DNA identified differentially methylated regions (DMRs) associated with prognostic mutations in older ( 60 years) cytogenetically normal (CN) patients with AML (n = 134). Genes with promoter DMRs and expression levels significantly associated with outcome were used to compute a prognostic gene expression weighted summary score that was tested and …
Gas6 Expression Identifies High-Risk Adult Aml Patients: Potential Implications For Therapy, S. P. Whitman, J. Kohlschmidt, K. Maharry, S. Volinia, K. Mrozek, D. Nicolet, S. Schwind, H. Becker, J. E. Kolitz, C. D. Bloomfield, +11 Additional Authors
Gas6 Expression Identifies High-Risk Adult Aml Patients: Potential Implications For Therapy, S. P. Whitman, J. Kohlschmidt, K. Maharry, S. Volinia, K. Mrozek, D. Nicolet, S. Schwind, H. Becker, J. E. Kolitz, C. D. Bloomfield, +11 Additional Authors
Journal Articles
Emerging data demonstrate important roles for the TYRO3/AXL/MERTK receptor tyrosine kinase (TAM RTK) family in diverse cancers. We investigated the prognostic relevance of GAS6 expression, encoding the common TAM RTK ligand, in 270 adults (n=71 aged <60 >years; n=199 aged >= 60 years) with de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients expressing GAS6 (GAS6+), especially those aged >= 60 years, more often failed to achieve a complete remission (CR). In all patients, GAS6+ patients had shorter disease-free (DFS) and overall (OS) survival than patients without GAS6 expression (GAS6-). After adjusting for other prognostic markers, GAS6+ predicted CR failure (P=0.02), …
Idelalisib And Rituximab In Relapsed Chronic Lymphocytic Leukemia, R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, S. M. O'Brien, +17 Additional Authors
Idelalisib And Rituximab In Relapsed Chronic Lymphocytic Leukemia, R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, S. M. O'Brien, +17 Additional Authors
Journal Articles
BackgroundPatients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population. MethodsIn this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo. We randomly assigned 220 patients with decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily. …
Ibrutinib Versus Ofatumumab In Previously Treated Chronic Lymphoid Leukemia, J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, P. Hillmen, +25 Additional Authors
Ibrutinib Versus Ofatumumab In Previously Treated Chronic Lymphoid Leukemia, J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, P. Hillmen, +25 Additional Authors
Journal Articles
Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome. Methods In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response …
Igm Myeloma Or Waldenstrom's Macroglobulinemia Is The Big Question?, V. R. Bhatt, S. Murukutla, M. Naqi, S. Pant, S. Kedia, T. Terjanian
Igm Myeloma Or Waldenstrom's Macroglobulinemia Is The Big Question?, V. R. Bhatt, S. Murukutla, M. Naqi, S. Pant, S. Kedia, T. Terjanian
Journal Articles
ABSTRACT: Although critical from therapeutic and prognostic perspectives, differentiating IgM Myeloma (MM) from Waldenstrom's macroglobulinemia (WM) is fraught with failure. WM can usually be distinguished from IgM MM by the lymphoplasmacytic versus pure plasmacytic morphology, absent versus present lytic bone lesions, and immunophenotypic findings. However, all these features have their own limitations; hence, it requires constant vigilance and periodic re-evaluation. Here we describe a case of a 70-year-old woman initially diagnosed as smoldering IgM MM, who eventually turned out to have WM.
Ighv1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React With Hiv-1 And Hepatitis C Virus Antigens As Well As Intestinal Commensal Bacteria, K. K. Hwang, A. M. Trama, D. M. Kozink, S. L. Allen, K. R. Rai, R. Catera, X. J. Yan, C. C. Chu, N. Chiorazzi, B. F. Haynes, +12 Additional Authors
Ighv1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React With Hiv-1 And Hepatitis C Virus Antigens As Well As Intestinal Commensal Bacteria, K. K. Hwang, A. M. Trama, D. M. Kozink, S. L. Allen, K. R. Rai, R. Catera, X. J. Yan, C. C. Chu, N. Chiorazzi, B. F. Haynes, +12 Additional Authors
Journal Articles
IGHV1-B-cell chronic lymphocytic leukemia (B-CLL) patients expressing unmutated immunoglobulin heavy variable regions (IGHVs) use the IGHV1-69 B cell receptor (BCR) in 25% of cases. Since HIV-1 envelope gp41 antibodies also frequently use IGHV1-69 gene segments, we hypothesized that IGHV1-69 B-CLL precursors may contribute to the gp41 B cell response during HIV-1 infection. To test this hypothesis, we rescued 5 IGHV1-69 unmutated antibodies as heterohybridoma IgM paraproteins and as recombinant IgG(1) antibodies from B-CLL patients, determined their antigenic specificities and analyzed BCR sequences. IGHV1-69 B-CLL antibodies were enriched for reactivity with HIV-1 envelope gp41, influenza, hepatitis C virus E2 protein and …
Lenalidomide And Rituximab For The Initial Treatment Of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From The Chronic Lymphocytic Leukemia Research Consortium, D. F. James, L. Werner, J. R. Brown, W. G. Wierda, J. C. Barrientos, J. E. Castro, A. Greaves, A. J. Johnson, K. R. Rai, T. J. Kipps, +2 Additional Authors
Lenalidomide And Rituximab For The Initial Treatment Of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From The Chronic Lymphocytic Leukemia Research Consortium, D. F. James, L. Werner, J. R. Brown, W. G. Wierda, J. C. Barrientos, J. E. Castro, A. Greaves, A. J. Johnson, K. R. Rai, T. J. Kipps, +2 Additional Authors
Journal Articles
Purpose Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic leukemia (CLL). In preclinical models, lenalidomide acted synergistically with rituximab. The CLL Research Consortium initiated a phase II study to evaluate this combination in treatmentnaive patients. Patients and Methods Lenalidomide was initiated at 2.5 mg/day and was escalated based on treatment tolerability to a maximum of 10 mg/day, for 21 days/cycle, for a maximum of seven cycles. Rituximab was administered at the end of cycle 1 and was continued for seven cycles. Patients received allopurinol and aspirin for prophylaxis. Results Sixty-nine patients enrolled onto one of two age-specific …